Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis

被引：1
|
作者：
Colombel, Jean-Frederic [1 ]
Sandborn, William [2 ]
Wolf, Doug [3 ]
Panaccione, Remo [4 ]
Lazar, Andreas [5 ]
Kron, Martina [5 ]
Robinson, Anne [6 ]
Thakkar, Roopal [6 ]
机构：
[1] CHRU, Hop Huriez, Lille, Nord, France
[2] Univ Calif San Diego, La Jolla, CA 92093 USA
[3] Atlanta Gastroenterol Associates, Atlanta, GA USA
[4] Univ Calgary, Calgary, AB, Canada
[5] Abbott GmbH & Co KG, Ludwigshafen, Germany
[6] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
INFLAMMATORY BOWEL DISEASES | 2012年 / 18卷
关键词：
D O I：
10.1097/00054725-201212001-00052
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S20 / S21
页数：2
相关论文
共 50 条
  • [21] Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
    Suzuki, Yasuo
    Motoya, Satoshi
    Hanai, Hiroyuki
    Hibi, Toshifumi
    Nakamura, Shiro
    Lazar, Andreas
    Robinson, Anne Martin
    Skup, Martha
    Mostafa, Nael Mohamed
    Huang, Bidan
    Thakkar, Roopal
    Watanabe, Mamoru
    JOURNAL OF GASTROENTEROLOGY, 2017, 52 (09) : 1031 - 1040
  • [22] Long-Term Endoscopic and Histological Outcomes of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis With up to 3 Years of Treatment
    Sands, Bruce E.
    Kobayashi, Taku
    Wu, Jianmin
    Wang, Isabella Yali
    Zhu, Baojin
    Redondo, Isabel
    Peyrin-Biroulet, Laurent
    Walsh, Alissa
    Magro, Fernando
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1042 - S1043
  • [23] Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis
    Chen, Xinlin
    Hou, Jiangtao
    Yuan, Yujie
    Huang, Chaoyuan
    Liu, Tianwen
    Mo, Chuanwei
    Li, Haiwen
    Chen, Bin
    Xu, Qian
    Hou, Zhengkun
    He, Weiling
    Liu, Fengbin
    BIODRUGS, 2016, 30 (03) : 207 - 217
  • [24] Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis
    Xinlin Chen
    Jiangtao Hou
    Yujie Yuan
    Chaoyuan Huang
    Tianwen Liu
    Chuanwei Mo
    Haiwen Li
    Bin Chen
    Qian Xu
    Zhengkun Hou
    Weiling He
    Fengbin Liu
    BioDrugs, 2016, 30 : 207 - 217
  • [25] Golimumab for moderately to severely active ulcerative colitis
    Kedia, Saurabh
    Ahuja, Vineet
    Makharia, Govind K.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (10) : 1273 - 1282
  • [26] Guselkumab for moderately to severely active ulcerative colitis
    不详
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (02): : 112 - 112
  • [27] Filgotinib for moderately to severely active ulcerative colitis
    Mannucci, Alessandro
    D'Amico, Ferdinando
    El Saadi, Ahmad
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (10) : 927 - 940
  • [28] Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
    Yasuo Suzuki
    Satoshi Motoya
    Hiroyuki Hanai
    Toshifumi Hibi
    Shiro Nakamura
    Andreas Lazar
    Anne Martin Robinson
    Martha Skup
    Nael Mohamed Mostafa
    Bidan Huang
    Roopal Thakkar
    Mamoru Watanabe
    Journal of Gastroenterology, 2017, 52 : 1079 - 1079
  • [29] 52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants
    Reinisch, Walter
    Sandborn, William J.
    Panaccione, Remo
    Huang, Bidan
    Pollack, Paul F.
    Lazar, Andreas
    Thakkar, Roopal B.
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (08) : 1700 - 1709
  • [30] Effect of Adalimumab Dose Escalation on Hospitalization Risk in Patients With Moderately to Severely Active Ulcerative Colitis
    Feagan, Brian
    Skup, Martha
    Thakkar, Roopal
    Lazar, Andreas
    Yang, Min
    Macaulay, Dendy
    Chao, Jingdong
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S768 - S768
12345